Current anti-diabetic agents and their molecular targets: A review

N Kerru, A Singh-Pillay, P Awolade, P Singh - European Journal of …, 2018 - Elsevier
Diabetes mellitus is a medical condition characterized by the body's loss of control over
blood sugar. The frequency of diagnosed cases and consequential increases in medical …

Synthetic heterocyclic candidates as promising α-glucosidase inhibitors: An overview

M Dhameja, P Gupta - European journal of medicinal chemistry, 2019 - Elsevier
Abstract α-Glucosidase enzyme inhibition is an effective therapeutic decorum in the
treatment of type 2 diabetes mellitus. Since 1990, three α-glucosidase inhibitors are known …

Synthesis, characterization and bioactivity of new pyridine-2(H)-one, nicotinonitrile, and furo[2,3-b]pyridine derivatives

MM Ibrahim, MN Azmi, MB Alhawarri, NNSNM Kamal… - Molecular Diversity, 2024 - Springer
Pyridone heterocycles, such as furo [2, 3-b] pyridines, have emerged as prominent scaffolds
in medicinal chemistry due to their versatile pharmacological properties, including significant …

Biological evaluation of new imidazole derivatives tethered with indole moiety as potent α-glucosidase inhibitors

S Naureen, F Chaudhry, MA Munawar, M Ashraf… - Bioorganic …, 2018 - Elsevier
A series of triarylimidazoles substituted with 2-arylindoles (4a-4j) were prepared and
evaluated for their in vitro α-Glucosidase inhibition. α-Glucosidase inhibition assay …

Unravelling the roles of Autophagy in OSCC: A renewed perspective from mechanisms to potential applications

Q Gou, LL Zheng, H Huang - Frontiers in Pharmacology, 2022 - frontiersin.org
Oral squamous cell carcinoma (OSCC) is associated with a low survival rate and a high
disability rate, making it a serious health burden, particularly in Southeast Asian countries …

Discovery of novel anti-tumor compounds targeting PARP-1 with induction of autophagy through in silico and in vitro screening

D Shi, Q Pang, Q Qin, X Yao, X Yao, Y Yu - Frontiers in Pharmacology, 2022 - frontiersin.org
Poly (ADP-ribose) polymerase 1 (PARP-1) is a critical enzyme involved in DNA damage
repair and recombination, and shows great potential for drug development in the treatment …

Discovery of novel EGFR inhibitor targeting wild-type and mutant forms of EGFR: in silico and in vitro study

D Todsaporn, A Zubenko, V Kartsev, T Aiebchun… - Molecules, 2023 - mdpi.com
Targeting L858R/T790M and L858R/T790M/C797S mutant EGFR is a critical challenge in
developing EGFR tyrosine kinase inhibitors to overcome drug resistance in non-small cell …

A Review on the Development of Novel Heterocycles as α-Glucosidase Inhibitors for the Treatment of Type-2 Diabetes Mellitus

P Patel, D Shah, T Bambharoliya, V Patel… - Medicinal …, 2024 - ingentaconnect.com
One of the most effective therapeutic decencies in the treatment of Type 2 Diabetes Mellitus
is the inhibition of α-glucosidase enzyme, which is present at the brush border of the …

Furopyridine Derivatives as Potent Inhibitors of the Wild Type, L858R/T790M, and L858R/T790M/C797S EGFR

D Todsaporn, A Zubenko, VG Kartsev… - The Journal of …, 2024 - ACS Publications
The treatment of patients with nonsmall cell lung cancer (NSCLC) using epidermal growth
factor receptor (EGFR) inhibitors is complicated by drug-sensitive activating L858R/T790M …

Transcriptome analysis predicts mode of action of benzimidazole molecules against Staphylococcus aureus UAMS‐1

D Chauhan, S Hati, R Priyadarshini… - Drug Development …, 2019 - Wiley Online Library
Antimicrobial drug resistance is one of the most critical problems that plagued the human
race in modern times. Discovery of novel antibiotics is important to counter this threat …